Immunovant
Update in progressIMVT (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Immunovant is a clinical-stage immunology company developing monoclonal antibodies for autoimmune diseases. It is advancing IMVT-1402 for Graves’ disease, rheumatoid arthritis, myasthenia gravis, CIDP, cutaneous lupus erythematosus, and Sjögren’s syndrome; and batoclimab for myasthenia gravis, CIDP, and thyroid eye disease. Founded in 2018 and based in New York, Immunovant is a subsidiary of Roivant Sciences Ltd.
Company score
- Sentiment
- 0.20
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.22
- Governance
- 0.00
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.07
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.13
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGS (NMS)
- LocationUnited States
- CEODr. Eric Venker M.D., Pharm.D.
- Founded2018
- Employees315
- Websiteimmunovant.com
Identifiers
- ISINUS45258J1025
- FIGIBBG00P5MC0Q8
- CUSIP42227C102
- CIK0001764013